Type of adverse event: allergic reactions/hypotension · people with CKD
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
1 finding from 1 review
Gastrointestinal effects · people with CKD
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
1 finding from 1 review
Type of adverse event: infection · people with CKD
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
1 finding from 1 review
Numbers of non‐dialysis patients needing to commence dialysis · people with CKD
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
1 finding from 1 review
Blood transfusion · people with CKD
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
1 finding from 1 review
Intervention not reported
Number achieving target Hb or increase ≥1 g/dL · adults and children with CKD
The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).
1 finding from 1 review
Intervention not reported
Hb: final or change (g/dL) · adults and children with CKD
1 finding from 1 review
Intervention not reported
All‐cause mortality · people with liver metastases
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cancer mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
All adverse events and complications · people with liver metastases
The intervention led to higher all adverse events and complications; GRADE not reported.
1 finding from 1 review
Intervention not reported
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Recurrence of liver metastases Number of participants developing recurrences of liver metastases · people with liver metastases
The intervention showed no clear difference in recurrence of liver metastases Number of participants developing… (low certainty).
1 finding from 1 review
Intervention not reported
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Tumour response measures · people with liver metastases
1 finding from 1 review
50% or greater reduction in seizure frequency · people with focal epilepsy
Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with focal epilepsy
Losigamone probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · people with focal epilepsy
Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in urinary GAG excretion from baseline · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mean percentage change from baseline in FVC (% predicted) · adults and children with mucopolysaccharidosis I
1 finding from 1 review